ANAVEX LIFE SCIENCES CORP. 8K

Anavex Life Sciences Corp. is refreshing its board, formalizing an Executive Committee, opposing a dissident control slate from PVG Asset Management and Patrick S. Adams, and has filed a preliminary proxy statement ahead of its 2026 Annual Meeting while emphasizing its strategic focus on lead candidate blarcamesine.

Anavex Life Sciences Corp. announced a board refresh and proxy campaign plans in advance of its 2026 Annual Meeting, including nominating two new independent directors, Gautam Patel and Dr. Adrian Senderowicz, to stand for election alongside four incumbent independent directors, confirming that former CEO Christopher Missling and director Dr. Steffen Thomas will not be renominated and will leave the board after the meeting, and highlighting the establishment of an Executive Committee to manage the company’s affairs while urging stockholders to reject a competing control slate proposed by PVG Asset Management Corporation and Patrick S. Adams in a preliminary proxy statement the Anavex board characterizes as deficient and misleading; the company also noted an interim CEO appointment, a delayed quarterly filing, a continued strategic focus on its lead drug candidate blarcamesine (ANAVEX2‑73) across several CNS indications, and the filing of its own preliminary proxy statement with the SEC, with plans to solicit votes on a WHITE proxy card for its six-nominee slate.

Filing Facts

CIK

1314052

Ticker

-

Form

8K

Source Type

sec

Accession

0001731122-26-001000

Alert Tier

6